Financial Performance - The company's revenue for the six months ended September 30, 2023, was approximately HKD 93,373,000, an increase of about 3.58% compared to HKD 90,146,000 for the same period in 2022, driven by growth in the hemodialysis business[6]. - The operating loss attributable to the company's owners for the period was approximately HKD 3,050,000, compared to a loss of HKD 2,506,000 in 2022[6]. - Basic and diluted loss per share was approximately HKD 0.54, compared to HKD 0.45 in 2022[8]. - The total comprehensive loss for the period was approximately HKD 7,418,000, compared to HKD 13,425,000 in 2022[8]. - The company reported a loss of HKD (3,050,000) for the period ended April 1, 2023, compared to a loss of HKD (2,506,000) for the previous period[12]. - The group recorded a loss attributable to the owners of the company of approximately HKD 3,050,000 for the period, compared to a loss of approximately HKD 2,506,000 in the same period in 2022[71]. Cash and Liquidity - Total cash and cash equivalents as of September 30, 2023, were approximately HKD 15,765,000, up from HKD 9,876,000 as of March 31, 2023[6]. - The net cash generated from operating activities for the six months ended September 30, 2023, was HKD 10,056,000, a decrease of 27.5% compared to HKD 13,905,000 in the same period of 2022[21]. - The net cash used in investing activities for the six months ended September 30, 2023, was HKD (254,000), an improvement from HKD (442,000) in the previous year[21]. - The net cash generated from financing activities for the six months ended September 30, 2023, was HKD 1,384,000, down from HKD 4,079,000 in the same period of 2022[21]. - The cash and cash equivalents increased to HKD 15,765,000 as of September 30, 2023, compared to HKD 13,204,000 at the same time last year[21]. - The current ratio as of September 30, 2023, was approximately 1.72, down from approximately 2.02 as of March 31, 2023, indicating a decrease in liquidity[75]. Assets and Liabilities - The company's total assets as of September 30, 2023, were approximately HKD 175,272,000, compared to HKD 173,448,000 as of March 31, 2023[10]. - Current liabilities increased to approximately HKD 49,143,000 as of September 30, 2023, from HKD 35,236,000 as of March 31, 2023[11]. - Non-current assets decreased to approximately HKD 90,747,000 as of September 30, 2023, from HKD 96,579,000 as of March 31, 2023[10]. - The company's total liabilities as of September 30, 2023, were not explicitly stated but can be inferred from the equity and cash flow data presented[12]. - Total liabilities as of September 30, 2023, were HKD 62,287,000, with HKD 53,905,000 classified under pharmaceutical wholesale and dialysis services[37]. Revenue Breakdown - Total revenue for the six months ended September 30, 2023, was HKD 93,373,000, with HKD 25,139,000 from pharmaceutical wholesale and distribution, and HKD 68,234,000 from dialysis treatment and consulting services[32]. - Revenue from the wholesale business was approximately HKD 25,139,000, a decrease of about 8.78% compared to HKD 27,560,000 in 2022[55]. - Revenue from the blood dialysis business increased to approximately HKD 68,234,000, representing a growth of about 9.02% from HKD 62,586,000 in 2022[56]. - The company recorded a profit of approximately HKD 2,473,000 from the blood dialysis business, up from HKD 2,089,000 in 2022[56]. - Other income and revenue for the period was approximately HKD 3,011,000, an increase of about HKD 2,752,000 compared to the same period in 2022, mainly from the sale of a self-operated hemodialysis treatment center in Guangdong, China[65]. Expenses - Selling and distribution expenses were approximately HKD 19,791,000, an increase of about HKD 1,792,000 or approximately 9.96% compared to the same period in 2022, mainly due to increased marketing and logistics costs[66]. - Administrative expenses were approximately HKD 11,883,000, an increase of about HKD 1,733,000 or approximately 17.07% compared to the same period in 2022, primarily due to increases in depreciation, travel, and general office expenses[67]. - The company incurred financial expenses of HKD 893,000 for the six months ended September 30, 2023, down from HKD 938,000 in the same period of 2022[40]. - Depreciation of property, plant, and equipment for the period was HKD 4,368,000, compared to HKD 2,761,000 in the previous year[39]. Shareholder Information - As of September 30, 2023, Mr. Wang holds a total equity interest of 168,755,611 shares, representing approximately 30.12% of the issued shares[85]. - The company has a total of 156,862,198 shares held by Wei Yang Investment Development Limited, which accounts for about 28.00% of the issued shares[89]. - The total equity interest of major shareholders, including Expert Wealth Investments Limited and Hong Kong Financial Limited, is also 156,862,198 shares, representing approximately 28.00%[89]. - The shares held by Wei Yang are pledged to Hong Kong Financial Limited, which is wholly owned by Expert Wealth Investments Limited[89]. Corporate Governance - The company has adopted a code of conduct for directors regarding securities trading, which complies with the standard code[97]. - The company has maintained a high level of corporate governance and has fully complied with the corporate governance code during the reporting period[98]. - The company has not established a chairman position since the resignation of the previous chairman in 2014, and the board believes current members can share the responsibilities effectively[98]. - The audit committee has reviewed the group's unaudited condensed consolidated results for the period and believes they have been prepared in accordance with applicable accounting standards[105]. - The interim report has been published on both the Hong Kong Stock Exchange website and the company's website[107].
万嘉集团(00401) - 2024 - 中期财报